Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease. - Wikidata - wikimedia - TriplyDB

Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease.

Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease.

http://www.wikidata.org/entity/Q42792348

about

Multiple Aspects of Gene Dysregulation in Huntington's Disease Mouse models of polyglutamine diseases: review and data table. Part I PGC-1α, mitochondrial dysfunction, and Huntington's disease Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes Mitochondrial dysfunction in neurodegenerative diseases Robust MR-based approaches to quantifying white matter structure and structure/function alterations in Huntington's disease.Tractography of the corpus callosum in Huntington's disease.Metabolic stress modulates Alzheimer's β-secretase gene transcription via SIRT1-PPARγ-PGC-1 in neurons.Developmental alterations in motor coordination and medium spiny neuron markers in mice lacking pgc-1α Deep white matter in Huntington's disease Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing.Reduction of mutant ataxin-7 expression restores motor function and prevents cerebellar synaptic reorganization in a conditional mouse model of SCA7 CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases Striatal oligodendrogliogenesis and neuroblast recruitment are increased in the R6/2 mouse model of Huntington's disease Changes in gene expression within the ventral tegmental area following repeated excessive binge-like alcohol drinking by alcohol-preferring (P) rats.Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.Network analysis of human post-mortem microarrays reveals novel genes, microRNAs, and mechanistic scenarios of potential importance in fighting huntington's disease.Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease.Molecular patterns of neurodevelopmental preconditioning: a study of the effects of antenatal steroid therapy in a protein-restriction mouse model.PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond.Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease Energy dysfunction in Huntington's disease: insights from PGC-1α, AMPK, and CKB.An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity Peroxisome proliferator-activated receptor-γ cofactors in neurodegeneration.Mitochondrial dysfunction in central nervous system white matter disorders.HDL and cholesterol handling in the brain.Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction.FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models Microstructural brain abnormalities in Huntington's disease: A two-year follow-up.Peroxisome proliferator-activated receptor gamma-coactivator-1 alpha coordinates sphingolipid metabolism, lipid raft composition and myelin protein synthesis.The Corticospinal Tract in Huntington's Disease.Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes.Intracellular Cholesterol Trafficking and Impact in Neurodegeneration.

P2860

Q24605880-ABDB82CC-F60B-4464-98FA-18003D435D7F Q26853025-D35CD32A-7C5D-4C55-BEB6-7AAEB8EEB1D2 Q27001671-613B6C3A-2036-4827-8CB4-6678A5D8E7BF Q27305777-7E1A932E-A157-4A3C-8280-ABDF88EE88DC Q28387647-CE70C6DD-ABEC-4441-9D27-15C0F00BE97D Q30991345-889231DF-164B-41FF-AB20-8549E101B5BC Q31137452-2BB83D93-DB3A-4CFD-8748-088D15A5DE30 Q33579072-29A87F6F-3F19-456B-B6A8-23C9B030C5D1 Q34391101-A11AE040-07E6-486C-85EE-EA2B9D843563 Q34394979-E6BB623E-5D70-44C0-8233-96E925B82DBA Q35253106-FE74A63F-4B4E-404A-AAF5-26B3FB2C4D43 Q35747131-FD4D5E7D-AB30-44EC-9A8C-24CD3107E1D6 Q35750228-2CCED417-BFEA-452F-923F-42B1EC8EF215 Q36064007-DC376D9C-E463-4E2B-9697-9A30015AD655 Q36580728-A29779E5-A202-4245-A488-C9DC52A437F2 Q36615488-2FEF5B30-BC8E-4DA9-99FB-6CFF59271459 Q36678075-E8A1B0C9-4D39-40D5-BFB8-F875608865CE Q36761088-A649408F-A87F-4981-8C4D-C274FD0CB09B Q36771650-A91F4536-C0A7-4DD1-A199-4BC72C73B96B Q36934002-07D71712-5744-4DB6-A780-4C6032DD77E7 Q36991464-FAD90DDA-EF76-4316-8EA0-FCE4F52550F9 Q37368003-A3B6DEEF-1092-4E76-9D82-696B223FF521 Q37453183-259605F6-38AF-488E-8B17-1DD97AB5CC77 Q37530250-DDF2C9AD-3720-402F-85C0-76CE29BEACD1 Q37686708-AEE24FC5-79C1-4630-8ECB-AFFBF91BC9C1 Q37958488-F9010BAF-7CA7-4D38-BF8D-32053A3B204A Q37996350-DC43F446-885C-4B8A-8325-5BCCAE995D7E Q38013005-D596AAEA-6A08-4801-A07D-88C3BD85D64A Q38038981-2B91581F-6EDB-4139-AA81-0D8934F43660 Q38058026-2E01F457-EF66-4BC2-ABC7-F5310D48D669 Q38215315-221D3305-6180-4016-AC57-0A9A6AEEFDEE Q38218439-D4CAAF16-6658-4778-9476-730CC504CA0E Q38813613-3EB70F5D-62C6-4C41-B9AE-C76158C69B20 Q39049796-739BC0ED-BD5D-4493-8923-8024E011EEF4 Q41340916-6D2E5055-EE75-46BC-A227-061F01EFB797 Q41490462-69035820-E8E5-49F4-92AD-FDEF2FCF6863 Q44952714-09CBCFFC-3C14-44F2-8B64-273C88ECB273 Q45298673-A3BA73BE-DD57-426F-B7A2-0A93D98B265A Q45305662-D34AE0F6-908A-4EA5-B93B-60586B8253BE Q45305840-88274FFE-051B-4293-BABA-583A16841A8D

P2860

Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease.

http://www.wikidata.org/entity/Q42792348

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Peroxisome-proliferator-activa ...... odels of Huntington's disease.

@en

Peroxisome-proliferator-activa ...... odels of Huntington's disease.

@nl

type

label

Peroxisome-proliferator-activa ...... odels of Huntington's disease.

@en

Peroxisome-proliferator-activa ...... odels of Huntington's disease.

@nl

prefLabel

Peroxisome-proliferator-activa ...... odels of Huntington's disease.

@en

Peroxisome-proliferator-activa ...... odels of Huntington's disease.

@nl

P1433

Q42792348-122B4753-06F2-4A3C-A2E6-0A9469DEDCAD

P1476

Q42792348-F1BE8002-1A68-4676-ACAB-14452285240D

P2093

Q42792348-0C2AAE8B-DCA0-4065-93A4-067366AB1AD8

Q42792348-0ECC0B09-19E0-4290-9AE8-05585271B2FD

Q42792348-144B304E-04DE-4BD0-940C-96816B563C9D

Q42792348-15390094-BEDC-4119-BBDE-00D8B9EE48BA

Q42792348-2C8AD566-65A5-4D8F-A87B-7C71E7CDD92E

Q42792348-514B53E4-17DB-4FCC-986F-56A3229CF053

Q42792348-63724DE4-4BAA-4F4C-823E-FFA9A37243A0

Q42792348-91EA6DBB-048E-48F6-8E1F-8E2BBBB676D6

Q42792348-AE01F578-42C7-423C-A5E9-7A957A9391BC

P2860

Q42792348-033C3161-840E-4D48-9E79-B73AF479D806

Q42792348-0B1B065C-C186-490E-9A10-62D8CCC33420

Q42792348-0F78F5C8-7719-4DA6-8564-503F339A4B2B

Q42792348-19ED735D-BE46-4ED3-BFDD-11759A6F3C40

Q42792348-1C7E0B3E-76CE-4BE2-871D-EB18B90AC8EE

Q42792348-297D62EE-D59F-443E-A122-6674BB76BA27

Q42792348-2A15DBCB-E677-4364-B2BC-4A7EC9B47518

Q42792348-2D37A093-AF1F-4E50-AA30-CB9060DB5F7F

Q42792348-3392B0F6-C8B7-480F-BE1E-06F74EAFACFF

Q42792348-36EF6983-A4B1-43CA-B1F6-87EC79420AB8

P304

Q42792348-C9C8AED7-E5BE-4E07-AE5A-1E8AA6473EA3

P31

Q42792348-0EF18B4C-B1AC-47DD-8088-752CDEDFC7F1

P356

Q42792348-48520F0E-CDF3-4AA7-8662-A270085E7C9A

P407

Q42792348-296EA91B-35E6-474A-8335-FE5BFBB696B9

P433

Q42792348-AF50DD28-FE30-472C-B435-9680F7904838

P478

Q42792348-C68BC3EB-D730-4F85-A70E-9085F84793CE

P50

Q42792348-4A1B69F2-D9D4-41AB-AA1F-A3DDF48FC3F8

Q42792348-7A0322E8-79FC-4EDC-B104-2481D0AD6EBF

Q42792348-8F08A365-A1BE-4E4A-9BAD-EDC2B00B78DF

P577

Q42792348-59885A23-706A-4D4D-A937-3A56782FE6EC

P698

Q42792348-12C4D540-BD3E-4624-8D6D-DEBC32563B00

P921

Q42792348-FAFDA33E-BEC7-41D5-8ED4-1484BA658AAB

P932

Q42792348-EA9958E4-0646-496D-9D65-3D394A061C5F

P356

JNEUROSCI.1291-11.2011

P1433

Journal of Neuroscience

P1476

Peroxisome-proliferator-activa ...... odels of Huntington's disease.

@en

P2093

Dimitri Krainc

http://www.w3.org/2001/XMLSchema#string

Elisa Brilli

http://www.w3.org/2001/XMLSchema#string

Hyun-Kyung Jeong

http://www.w3.org/2001/XMLSchema#string

Libin Cui

http://www.w3.org/2001/XMLSchema#string

Qi Peng

http://www.w3.org/2001/XMLSchema#string

Steven A Reeves

http://www.w3.org/2001/XMLSchema#string

Valerio Leoni

http://www.w3.org/2001/XMLSchema#string

Wenzhen Duan

http://www.w3.org/2001/XMLSchema#string

Zhongmin Xiang

http://www.w3.org/2001/XMLSchema#string

P2860

Potentiation of liver X receptor transcriptional activity by peroxisome-proliferator-activated receptor gamma co-activator 1 alpha

PGC-1 coactivators: inducible regulators of energy metabolism in health and disease

PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis

A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis

Differential expression of cholesterol hydroxylases in Alzheimer's disease

Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI

An oligodendrocyte-specific zinc-finger transcription regulator cooperates with Olig2 to promote oligodendrocyte differentiation

Localization of the transcriptional coactivator PGC-1alpha to GABAergic neurons during maturation of the rat brain

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice

P304

9544-9553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.1291-11.2011

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Jiangyang Zhang

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21715619

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

3132810

http://www.w3.org/2001/XMLSchema#string